NFE2L2 and non-small cell lung carcinoma: This was also seen in a separate study of KRAS mutant NSCLC patients in which it was identified that a co-occuring mutation in KEAP1 or NRF2 was a significant and independent risk factor for resistance to immunotherapy [75].